Xinqiao Biotech stock price decline draws attention alongside executive share purchase plan

K-LinePoet · 2026-03-04T21:53:18+00:00

The decline in New Bridge Bio's stock price coincides with the management's increased shareholding plan, mainly due to factors such as low average daily trading volume, poor company performance, and lack of investor confidence. Despite positive clinical data, concerns remain in the market due to long-term profitability gaps and historical partnership risks.

K-LinePoet

2026-03-04 21:53:18

Abstract generation in progress

CIC News: New Bridge Bio (NBP.OQ) recently experienced a decline in stock price alongside plans for senior executives to increase their holdings. The main factors are as follows:

Stock Price and Capital Performance

On January 20, 2026, Executive Chairman Fu Wei announced plans to personally buy up to $5 million worth of company shares (approximately 35 million RMB). However, the company’s average daily trading volume is only about $3 million, making the purchase scale relatively large compared to market liquidity, which could short-term increase selling pressure. From February 9 to 12, 2026, the stock price continuously declined, with a total drop of 10.95%, including a 4.42% decline on February 12, closing at $3.24. Trading volume was only $790,000, indicating weak capital support.

Operational Performance

The company’s Q2 2025 financial report shows zero revenue and a net loss of $5.52 million attributable to shareholders, with basic earnings per share of -$0.07. No products have yet achieved commercialization. Although the core pipeline Givastomig showed positive data, such as a 77% objective response rate in first-line gastric cancer treatment, the market worries about the long cycle from clinical results to revenue conversion. Coupled with the overall volatility in the biotech sector (NASDAQ index down 2.03% during the same period), investor confidence remains under pressure.

Company Fundamentals

In 2024, New Bridge Bio was forced to withdraw its CD47-targeting drug, Leronlimab, from AbbVie, leading to the company divesting its China operations to ease contractual obligations. Past partnership risks still influence market expectations. Although senior executives’ increased holdings signal long-term confidence, the company had accumulated losses of $239 million by 2025, and all core products are still in development stages, making short-term profitability unlikely to cover the losses.

The above information is compiled from public sources and does not constitute investment advice.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.